Mirna Therapeutics, Inc. MIRN
No live quote for MIRN yet.
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 1
- 2 months ago 1
- 3 months ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.12 | -0.12 – -0.12 | -0.26 | +53.8% | 0 | 0.0% | 1 |
| Next quarter | -0.12 | -0.12 – -0.12 | -0.21 | +42.9% | 0 | 0.0% | 1 |
| Current year | -0.43 | -0.43 – -0.43 | -1.05 | +59.0% | 0 | 0.0% | 1 |
| Next year | -0.48 | -0.48 – -0.48 | -0.43 | -11.6% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2016 | H.C. Wainwright | Downgrade | — | Neutral |
| Sep 20, 2016 | Cantor Fitzgerald | Downgrade | — | Hold |
| Sep 20, 2016 | Oppenheimer | Downgrade | — | Perform |
| Sep 11, 2016 | H.C. Wainwright | Initiated | — | Buy |
| Aug 15, 2016 | Citigroup | Downgrade | — | Neutral |
| Aug 15, 2016 | Leerink Swann | Downgrade | — | Market Perform |
| Oct 25, 2015 | Cantor Fitzgerald | Initiated | — | Buy |
| Oct 25, 2015 | Leerink Swann | Initiated | — | Outperform |
| Oct 25, 2015 | Oppenheimer | Initiated | — | Outperform |